


**CLAIMS**

- 5 1. Use of a compound for preparing a pharmaceutical composition for treating a cerebrovascular pathology, the compound being represented by the following general formula (I) :



10

in which

- G represents an oxygen atom, a sulfur atom or a N-R<sub>4</sub> group,
- R<sub>4</sub> is a hydrogen atom or a linear or branched alkyl group, saturated or not, optionally substituted, containing from 1 to 5 carbon atoms,
- 15 • R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub>, which are the same or different, represent a hydrogen atom, a CO-R group or a group corresponding to the formula CO-(CH<sub>2</sub>)<sub>2n+1</sub>-X-R', at least one of the groups R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> is a group corresponding to the formula CO-(CH<sub>2</sub>)<sub>2n+1</sub>-X-R',
- R is a linear or branched alkyl group, saturated or not, optionally substituted, the main chain of which contains from 1 to 25 carbon atoms,
- 20 • X is a sulfur atom, a selenium atom, a SO group or a SO<sub>2</sub> group,
- n is a whole number comprised between 0 and 11,
- R' is a linear or branched alkyl group, saturated or not, optionally substituted, the main chain of which contains from 2 to 23, preferably 10 to 23, carbon atoms and possibly one or more heterogroups selected in the group consisting of an oxygen atom, a sulfur atom, a selenium atom, a SO group and a SO<sub>2</sub> group.
- 25

2. Use according to claim 1, in which the cerebrovascular pathology is cerebral ischemia or hemorrhagic stroke.

3. Use according to one of claims 1 and 2, characterized in that the R group or groups, which are the same or different, represent a linear or branched alkyl group, saturated or unsaturated, substituted or not, the main chain of which contains from 1 to 20 carbon atoms, preferably from 7 to 17 carbon atoms, even more preferably 14 to 17 carbon atoms.

4. Use according to any one of claims 1 to 3, characterized in that the R' group or groups, which are the same or different, represent a linear or branched alkyl group, saturated or unsaturated, substituted or not, the main chain of which contains from 12 to 23 carbon atoms, even more preferably from 13 to 20 carbon atoms, advantageously from 14 to 17 carbon atoms.

5. Use according to any one of the previous claims, characterized in that the R group or groups, which are the same or different, are selected in the group consisting of  $C_7H_{15}$ ,  $C_{10}H_{21}$ ,  $C_{11}H_{23}$ ,  $C_{12}H_{25}$ ,  $C_{13}H_{27}$ ,  $C_{14}H_{29}$ ,  $C_{16}H_{33}$ ,  $C_{17}H_{35}$ ,  $C_{15}H_{31}$ ,  $C_{14}H_{27}$ ,  $C_{14}H_{25}$ ,  $C_{15}H_{29}$ ,  $C_{17}H_{29}$ ,  $C_{17}H_{31}$ ,  $C_{17}H_{33}$ ,  $C_{19}H_{29}$ ,  $C_{19}H_{31}$ ,  $C_{21}H_{31}$ ,  $C_{21}H_{35}$ ,  $C_{21}H_{37}$ ,  $C_{21}H_{39}$ ,  $C_{23}H_{45}$ , the alkyl chains of eicosapentanoic acid (EPA)  $C_{20:5}$  (5, 8, 11, 14, 17) and docosahexanoic acid (DHA)  $C_{22:6}$  (4, 7, 10, 13, 16, 19),  $(CH_2)_n-CH(CH_3)C_2H_5$ ,  $(CH=C(CH_3)(CH_2)_2)_{n'}-CH=C(CH_3)_2$  and  $(CH_2)_{2x+1}-C(CH_3)_2-(CH_2)_{n''}-CH_3$ , x being a whole number equal to or comprised between 1 and 11, n' being a whole number equal to or comprised between 1 and 22, n'' being a whole number equal to or comprised between 1 and 5, n''' being a whole number equal to or comprised between 0 and 22 and  $(2x+n''')$  being less than or equal to 22 preferably less than or equal to 20.

6. Use according to any one of the previous claims, characterized in that the R' group or groups, which are the same or different, are selected in the group consisting of  $C_7H_{15}$ ,  $C_{10}H_{21}$ ,  $C_{11}H_{23}$ ,  $C_{12}H_{25}$ ,  $C_{13}H_{27}$ ,  $C_{14}H_{29}$ ,  $C_{16}H_{33}$ ,  $C_{17}H_{35}$ ,  $C_{15}H_{31}$ ,  $C_{20:5}$  (5, 8, 11, 14, 17),  $C_{22:6}$  (4, 7, 10, 13, 16, 19),  $C_{14}H_{27}$ ,  $C_{14}H_{25}$ ,  $C_{15}H_{29}$ ,  $C_{17}H_{29}$ ,  $C_{17}H_{31}$ ,  $C_{17}H_{33}$ ,  $C_{19}H_{29}$ ,  $C_{19}H_{31}$ ,  $C_{21}H_{31}$ ,  $C_{21}H_{35}$ ,  $C_{21}H_{37}$ ,  $C_{21}H_{39}$ ,  $C_{23}H_{45}$ .

$(\text{CH}_2)_n\text{-CH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $(\text{CH}=\text{C}(\text{CH}_3)(\text{CH}_2)_2)_{n'}\text{-CH}=\text{C}(\text{CH}_3)_2$  and  $(\text{CH}_2)_{2x+1}\text{-C}(\text{CH}_3)_2\text{-}(\text{CH}_2)_{n''}\text{-CH}_3$ ,  $x$  being a whole number equal to or comprised between 1 and 11,  $n'$  being a whole number equal to or comprised between 1 and 22,  $n''$  being a whole number equal to or comprised between 1 and 5,  $n'''$  being a whole number equal to or comprised between 0 and 22 and  $(2x+n''')$  being less than or equal to 22, preferably less than or equal to 20.

7. Use according to any one of the previous claims, characterized in that the R group or groups, which are the same or different, represent a lower alkyl group containing from 1 to 6 carbon atoms.

8. Use according to any one of the previous claims, characterized in that the R' group or groups, which are the same or different, are saturated and linear alkyl groups containing 14 carbon atoms.

9. Use according to any one of the previous claims, characterized in that the alkyl groups are substituted by one or more substituents, which are the same or different, selected in the group consisting of a halogen atom (iodine, chlorine, fluorine, bromine) and a OH, =O, NO<sub>2</sub>, NH<sub>2</sub>, CN, CH<sub>2</sub>-OH, O-CH<sub>3</sub>, CH<sub>2</sub>OCH<sub>3</sub>, CF<sub>3</sub> and COOZ group in which Z is a hydrogen atom or an alkyl group containing from 1 to 6 carbon atoms.

10. Use according to any one of the previous claims, characterized in that X is a sulfur or selenium atom, preferably a sulfur atom.

11. Use according to any one of the previous claims, characterized in that the group G represents an oxygen atom or a N-R<sub>4</sub> group and, when G is N-R<sub>4</sub>, R<sub>4</sub> preferably represents a hydrogen atom or a methyl group.

12. Use according to any one of the previous claims, characterized in that in the group CO-(CH<sub>2</sub>)<sub>2n+1</sub>-X-R',  $n$  is comprised between 0 and 3, more specifically comprised between 0 and 2, and in particular is equal to 0.

13. Use of formula (I) according to any one of the previous claims, in which at least one of the groups R1, R2 and R3 represents a  $\text{CO}-(\text{CH}_2)_{2n+1}\text{-X-R'}$  group in which X represents a selenium atom or preferably a sulfur atom and/or R' is a saturated and linear alkyl group containing from 13 to 17 carbon atoms, preferably from 14 to 16, even more preferably 14 carbon atoms.
14. Use according to any one of the previous claims, characterized in that R2 is a group corresponding to the formula  $\text{CO}-(\text{CH}_2)_{2n+1}\text{-X-R'}$ , preferably in which X represents a selenium atom or preferably a sulfur atom and/or R' is a saturated and linear alkyl group containing from 13 to 17 carbon atoms, more preferably in which n is equal to 0, in particular a group having the formula  $\text{CO-CH}_2\text{-S-C}_{14}\text{H}_{29}$ .
15. Use according to claim 14, characterized in that R1 and R3, which are the same or different, represent a hydrogen atom or a CO-R group.
16. Use according to claim 15, characterized in that R1 and R3, which are the same or different, represent a CO-R group.
17. Use according to any one of claims 1 to 16, characterized in that two of the groups R1, R2 and R3 are  $\text{CO}-(\text{CH}_2)_{2n+1}\text{-X-R'}$  groups, which are the same or different, preferably in which X represents a selenium atom or preferably a sulfur atom and/or R' is a saturated and linear alkyl group containing from 13 to 17 carbon atoms, more preferably in which n is equal to 0, in particular  $\text{CO-CH}_2\text{-S-C}_{14}\text{H}_{29}$  groups.
18. Use according to any one of claims 1 to 16, characterized in that R1, R2 and R3, which are the same or different, preferably the same, are  $\text{CO}-(\text{CH}_2)_{2n+1}\text{-X-R'}$  groups, preferably in which X represents a selenium atom or preferably a sulfur atom and/or R' is a saturated and linear alkyl group containing from 13 to 17 carbon atoms, more preferably in which n is comprised between 0 and 3, and in particular equal to 0.

19. Use according to any one of claims 1 to 17, characterized in that R1, R2 and R3 represent CO-CH<sub>2</sub>-S-C<sub>14</sub>H<sub>29</sub> groups.
20. Use according to any one of claims 1 to 17, characterized in that one or two of the substituents R1, R2 or R3 is a COCH<sub>3</sub> group.
21. Use according to any one of the previous claims 1 to 10 and 12 to 20, characterized in that the group G represents a sulfur atom.
22. Compounds represented by formula (I) such as defined in claim 1, selected in the group consisting of :
- 1,3-ditetradecylthioacetyl-2-palmitoylglycerol;
  - 1,3-diacetyl-2-tetradecylthioacetylglycerol;
  - 1,3-dioctanoyl-2-tetradecylthioacetylglycerol;
  - 1,3-diundecanoyl-2-tetradecylthioacetylglycerol; and
  - 1,3-ditetradecylthioacetoxo-2-(2-tetradecylthio)methylcarbonylthio-propane.
23. A pharmaceutical composition, characterized in that it comprises, in a pharmaceutically acceptable vehicle, at least one compound represented by general formula (I) identified in claim 22.
24. A pharmaceutical composition according to the previous claim, intended for the treatment of cerebrovascular pathologies and more particularly cerebral ischemia or stroke.